

## Special Issue

# Research Update on Pheochromocytoma and Paraganglioma

### Message from the Guest Editor

Pheochromocytoma and paraganglioma are tumors of the adrenal medulla and extra-adrenal paraganglia, respectively. PGLs are divided into sympathetic PGLs and parasympathetic PGLs. PPGLs have long been called 10% tumors, and studies have focused on tumor location (adrenal or extra-adrenal), age (adult or children), metastatic status (benign or malignant), multiplicity, and pathology (hereditary or syndromic). Recent progress based on clinicopathologic data with long follow-up time, extensive gene analysis, and newly developed chemical and metabolomics analysis have revealed the novel faces of these tumors. At present, all PPGLs are recognized as malignant tumors with metastatic potential and subject to risk stratification. Relationships between types of gene mutation and metastasis, tumor location, patient age, and sex have been comprehensively clarified through metabolomics analysis.

---

### Guest Editor

Dr. Noriko Kimura

Department of Diagnostic Pathology/Clinical Research, Pathology Division, National Hospital Organization, Hakodate Hospital, Hakodate, Japan

---

### Deadline for manuscript submissions

closed (1 August 2021)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/53823](https://mdpi.com/si/53823)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)